TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Onesource Specl Pharma L
ONESOURCE

Onesource Specl Pharma L Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 62/100 · Average See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹1,602.6

Change

+8.0 (0.5%)

Open

₹1,601.6

Prev. Close

₹1,594.6

Day High

₹1,634.4

Day Low

₹1,567.0

Volume Analysis

Traded

227,395

Delivered

133,421

Delivery %

58.67%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (22.0%)

Weaknesses (2)

  • •Low return on equity (-1.09%)
  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year revenue growth (231.6%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,703.06 ₹1,668.73 ₹1,635.66 ₹1,601.33 ₹1,568.26 ₹1,533.93 ₹1,500.86
Fibonacci ₹1,668.73 ₹1,642.98 ₹1,627.08 ₹1,601.33 ₹1,575.58 ₹1,559.68 ₹1,533.93
Camarilla ₹1,621.14 ₹1,614.96 ₹1,608.78 ₹1,601.33 ₹1,596.42 ₹1,590.24 ₹1,584.07

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-10.35%

1 Week

+0.21%

1 Month

+4.59%

3 Months

-2.74%

6 Months

+11.57%

1 Year

-10.46%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-0.77%

Net margin -3.18% × asset turnover 0.17x × equity multiplier 1.42x

Company Overview

Sector

Healthcare

Market Cap

₹18,377 Cr

ROE

-1.09%

Book Value

₹509.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.

TopFund Analysis

Onesource Specl Pharma L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 62/100. The strongest factor is Financial Strength (100/100), while Cash Flow (1/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (22.0%); low return on equity (-1.09%); promoter holding is falling. Strong 3-year revenue growth (231.6%).

TopFund Score — Fundamentals Quality

62/100 — Average

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

100

Valuation

50

Cash Flow

1

Corporate Governance

27

Momentum

63

Institutional Ownership

82

Business Quality

38

Risk & Volatility

75

Liquidity

88

From Screener.in

  • −Stock is trading at 3.15 times its book value
  • −Company has low interest coverage ratio.
  • −Company has a low return on equity of -2.63% over last 3 years.
  • −Promoters have pledged 37.2% of their holding.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 25 Sep

Allotment of 900 Equity shares of Re. 1 each under ONESOURCE ESOP 2021 on September 25, 2026

Closure of Trading Window 25 Sep 25 Sep
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 25 Sep 25 Sep
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s 23 Sep

Shareholders appointed B S R & Co LLP as statutory auditors for five years from September 23, 2026.

Shareholder Meeting / Postal Ballot-Outcome of AGM 23 Sep

OneSource held its 19th AGM on September 23, 2026; shareholders approved audited statements, auditor appointment, and related-party transactions.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 34 56 73 292 334 393 426 327 376 290 428 449
Expenses + 72 67 76 228 257 251 243 239 269 273 336 326
Operating Profit -39 -10 -3 64 77 142 183 88 106 17 92 123
OPM % -114.0% -19.0% -3.8% 22.0% 23.0% 36.0% 43.0% 27.0% 28.0% 6.0% 21.0% 27.0%
Other Income + -32 -74 3 -1 -1 -94 2 2 3 -2 2 0
Interest 25 26 20 42 45 46 33 27 34 38 23 31
Depreciation 18 20 20 68 68 69 68 68 70 70 72 72
Profit before tax -114 -130 -40 -47 -37 -67 83 -4 6 -93 0 20
Tax % 0.0% 0.0% 0.0% -88.0% 12.0% 4.0% -19.0% -96.0% -83.0% -5.0% -1,630.0% -23.0%
Net Profit + -114 -130 -40 -6 -42 -69 98 0 10 -89 5 25
EPS in Rs — — — — — -6 9 0 1 -8 0 2
Raw PDF — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 21 132 39 172 1,445 1,422 1,543
Expenses + 93 229 199 254 978 1,117 1,204
Operating Profit -71 -97 -161 -82 467 304 339
OPM % -334.0% -73.0% -415.0% -48.0% 32.0% 21.0% 22.0%
Other Income + 1 4 -526 -143 -94 5 2
Interest 16 68 48 89 166 122 126
Depreciation 34 70 66 76 274 279 283
Profit before tax -121 -231 -800 -391 -68 -92 -67
Tax % 0.0% 0.0% 0.0% 0.0% -73.0% -20.0% —
Net Profit + -121 -231 -800 -391 -18 -74 -49
EPS in Rs — — — — -2 -6 -4
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 774 1,009 781 392 5,869 5,820
Borrowings + 386 1,154 864 562 772 1,276
Other Liabilities + 96 276 365 468 1,005 1,197
Total Liabilities 1,258 2,442 2,015 1,426 7,657 8,304
Fixed Assets + 633 1,231 1,361 863 6,118 6,017
CWIP 431 490 334 188 218 529
Investments 0 0 4 20 16 16
Other Assets + 195 722 314 356 1,305 1,742
Total Assets 1,258 2,442 2,015 1,426 7,657 8,304
Equity Capital 2 3 4 4 11 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -118 -416 -163 -107 -68 9
Cash from Investing Activity + -207 -692 -68 511 -201 -495
Cash from Financing Activity + 381 1,162 118 -391 412 359
Net Cash Flow 56 54 -112 13 143 -127
CFO/OP 164 430 108 130 -13 6
Free Cash Flow -325 -1,071 -207 -171 -196 -561

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 37.76% → 30.48%
  Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 32.24% 29.17% 33.42% 32.34% 32.01% 31.4% 26.95%
Promoters 37.76% 34.25% 29.78% 29.77% 29.93% 30.48% 30.48%
FII 17.44% 18.54% 18.69% 19.39% 19.24% 17.5% 19.19%
DII 12.56% 18.03% 18.09% 18.48% 18.8% 20.61% 23.37%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Onesource Specl Pharma L (this stock) 18,377 — 3.15 -1.09%
Pfizer Ltd 18,303 119.0 13.25 19.8%
Eris Lifesciences Limited 17,618 26.9 4.5 18.7%
Poly Medicure Limited 17,479 54.6 5.63 9.02%
Cohance Lifesciences Ltd 17,290 161.0 4.43 4.89%
Jubilant Pharmova Ltd 17,118 44.1 2.41 6.53%
Shilpa Medicare Ltd 19,821 69.7 7.67 8.99%

Which Mutual Funds Hold Onesource Specl Pharma L?

Frequently Asked Questions about Onesource Specl Pharma L

Community Sentiment

What are other investors saying about Onesource Specl Pharma L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.